Koen W. van Besien, MD, recaps a debate in which he argued that patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and TP53 mutations should undergo allogeneic stem cell transplantation.

Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.

Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.